Edwards Lifesciences Corporation (EW) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Edwards Lifesciences Corporation (EW) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • May 13, 2026

AI, Obesity Drugs, and Diagnostics Fuel Healthcare Growth

Healthcare is regaining momentum as innovation—especially AI‑driven drug discovery—creates new growth opportunities, according to Shivani Vohra. She points to obesity treatments from Eli Lilly (LLY) and Novo Nordisk (NVO), advances in diagnostics from Natera (NTRA), and continued strength in med tech leaders like Intuitive Surgical (ISRG) and Edwards Lifesciences (EW) as key areas of expansion.

Edwards Lifesciences Announces Appointment of CFO

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced the appointment of Theodora (“Doretta”) Mistras as the company's corporate vice president and chief financial officer (CFO), effective at the end of May. Mistras will succeed Scott Ullem, who announced in October his planned transition from the CFO role. Mistras joins Edwards from Viatris, where she has served as CFO since March 2024, leading the company's global finance organization and overseeing financial planni.

Business Wire • May 4, 2026

Ten-Year Pivotal Data Demonstrate Long-Term Durability of Edwards Lifesciences' Resilia Tissue

CHICAGO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced 10-year results from the COMMENCE aortic trial, reinforcing the long-term durability and sustained performance of its proprietary RESILIA tissue. The data were presented at the 106th American Association for Thoracic Surgery Annual Meeting. As evidence increasingly supports treating patients earlier in the valve disease pathway, the need for durable valve solutions continues to grow. The COMMENCE trial provides prospectiv.

Business Wire • May 2, 2026

Artisan Global Opportunities Fund Q1 2026 Portfolio Activity

During the quarter, we initiated new positions in Edwards Lifesciences, Eli Lilly and Roblox. In addition to Linde, Shopify and Amazon, we also added to Woodward and Spotify during the quarter. We ended our investment campaigns in Netflix, Snowflake and RELX during the quarter.

Seeking Alpha • Apr 29, 2026

Edwards Lifesciences to Present at the BofA Securities 2026 Health Care Conference

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced it will participate in the BofA Securities 2026 Health Care Conference on Tuesday, May 12, 2026. Bernard Zovighian, chief executive officer, will participate in a fireside chat at 3:40 p.m. Pacific Time. A live webcast of the discussion will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com, with an archived version accessible later the same day. About Edwards Lifesciences.

Business Wire • Apr 28, 2026

Riverwater Small Cap Strategy: Q1 2026 Buys, Sells, And Standouts

Modine Manufacturing led the way during the quarter, benefiting from secular demand in data center cooling and a well received spinoff of Modine Manufacturing's auto cooling business. Coming out of 2025, Adeia reported record revenue and profitability, supported by a surge in IP licensing activity. AtriCure remains well positioned given its first-mover advantage and deep integration within surgical workflows despite near-term competitive concerns from Edwards Lifesciences.

Seeking Alpha • Apr 27, 2026

Edwards Lifesciences Stock Surges On Heart Valve Devices Growth

Edwards Lifesciences Corp (NYSE:EW) shares are up on Friday as the company reported strong first-quarter results, highlighting growth in its transcatheter mitral and tricuspid therapies.

Benzinga • Apr 24, 2026

EW's Q1 Earnings Beat, Revenues Match, '26 View Up, Stock Climbs

Edwards Lifesciences beats on Q1 earnings, matches revenue estimates, lifts 2026 outlook as TAVR and TMTT growth accelerates; shares rise on stronger guidance and margin expansion.

Zacks Investment Research • Apr 24, 2026

Edwards Lifesciences beats quarterly estimates on robust demand for artificial heart valves

Edwards Lifesciences beat Wall Street first-quarter estimates on Thursday, driven by robust demand ​for its artificial valves used in complex ‌cardiac procedures, sending its shares up over 4% in extended trading.

Reuters • Apr 23, 2026